Trials / Completed
CompletedNCT05905653
Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Santen Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STN1012600 ophthalmic solution 0.002% | 1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days |
Timeline
- Start date
- 2023-05-25
- Primary completion
- 2023-06-21
- Completion
- 2023-06-21
- First posted
- 2023-06-15
- Last updated
- 2023-12-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05905653. Inclusion in this directory is not an endorsement.